Jul. 13 at 10:25 AM
$AGEN
Agenus lands a major private placement worth up to
$340M to support its next Phase 3 program.
$85M funded upfront, with up to
$255M available through future warrant exercises.
Capital is being directed toward the ROBBIN Phase 3 trial evaluating BOT + BAL as neoadjuvant therapy for high-risk MSS colorectal cancer, an area that has seen limited innovation for decades.
If all warrants are exercised, the cash runway could extend through 2031. First patient dosing is expected around Q1 2027, with pivotal data likely several years later.
Resources are also being reallocated from the BATTMAN program to prioritize this pivotal study.
This remains a long-duration clinical story rather than a near-term catalyst.
Also watching
$MRNA,
$BNTX,
$IOVA, and
$EXEL for additional oncology and immunotherapy opportunities.
Markets reward preparation more than reaction.
Visit my profile for more market insights, biotech ideas, and high-conviction stock setups.
